Veracyte, Inc. Veracyte, Inc.

Veracyte, Inc.

VCYT

Classement en actions #4409
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Prix de l'action
$43.77
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$3.52B
Changement (1 jour)
1.51%
Changement (1 an)
19.43%
Pays
US
Échange Veracyte, Inc. (VCYT)

Catégorie

Healthcare
EPS pour Veracyte, Inc. (VCYT)
EPS au June 2026 TTM : $1.44
Selon les derniers rapports financiers et le cours de l'action de Veracyte, Inc., l’EPS actuel de la société (TTM) est de $1.44. À la fin de 2023, la société avait un EPS de $-1.02 une augmentation par rapport à celui de 2022, qui était de $-0.51.
Historique de l'EPS de Veracyte, Inc. de 2011 à 2026
EPS à la fin de chaque année
Année EPS Changez
2026 (TTM) $1.44 350.00%
2024 $0.32 -131.37%
2023 $-1.02 100.00%
2022 $-0.51 -54.05%
2021 $-1.11 68.18%
2020 $-0.66 144.44%
2019 $-0.27 -56.45%
2018 $-0.62 -31.87%
2017 $-0.91 -16.51%
2016 $-1.09 -16.15%
2015 $-1.30 -4.41%
2014 $-1.36 -77.89%
2013 $-6.15 369.47%
2012 $-1.31 28.43%
2011 $-1.02 0.00%
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$18.62 1,193.06%
US
$5.65 292.36%
US
$-1.36 -194.44%
US
- -
CN
$5.09 253.47%
US